A new treatment for tackling epidermolysis bullosa
By Jordi Casals, president, EMEA, Amryt Pharma Epidermolysis bullosa (EB), sometimes described as “the worst…
November 14, 2022 - 3 minutes
By Jordi Casals, president, EMEA, Amryt Pharma Epidermolysis bullosa (EB), sometimes described as “the worst…
The U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license…
A new call for new therapies to treat skin diseases has been launched by global…
U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to…